Rhythm Pharmaceuticals, Inc. — FY 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. Although the request identifies 2023 Q4, this filing reports full-year results; it does not provide a clear standalone Q4 financial summary.
Business context
Rhythm is a commercial-stage biopharmaceutical company focused on rare neuroendocrine diseases affecting the MC4R pathway. Its sole marketed product is IMCIVREE (setmelanotide), approved for certain forms of obesity associated with BBS and POMC, PCSK1 or LEPR deficiency. The company is also developing setmelanotide for additional indications and advancing RM-718, oral candidate LB54640, and a congenital hyperinsulinism program.
Financial performance and liquidity
| Metric | FY 2023 | FY 2022 | Change / context |
|---|---|---|---|
| Product revenue, net | $77.4 million | $16.9 million | Up 359%; principally reflects growth in IMCIVREE sales |
| Total revenue | $77.4 million | $23.6 million | Up 228%; FY 2022 included $6.8 million of RareStone license revenue |
| Cost of sales | $9.3 million | $2.1 million | Up 336%; company expects cost of sales to remain about 10%–12% of product revenue |
| Gross margin | Approximately 88% | Approximately 87% | Calculated from product revenue less cost of sales |
| Research and development | $135.0 million | $108.6 million | Up 24% |
| Selling, general and administrative | $117.5 million | $92.0 million | Up 28% |
| Operating loss | $184.4 million | $179.2 million | Loss widened $5.2 million |
| Net loss | $184.7 million | $181.1 million | Loss widened $3.6 million; basic and diluted loss per share was $3.20 |
| Net cash used in operations | $136.2 million | $173.4 million | Cash use decreased year over year |
| Cash, cash equivalents and short-term investments | $275.8 million | $333.3 million | At December 31; includes $60.1 million cash and cash equivalents |
| Deferred royalty obligation | $106.1 million | $75.8 million | At December 31; debt-like RIFA carrying value |
Current assets were $308.3 million and current liabilities were $55.2 million at year-end. Management expects available cash and short-term investments to fund operations into the second half of 2025, while warning that plans may change and additional funding may be needed. The company has incurred losses since inception and does not expect near-term profitability.
Material changes and notable items
- Product revenue rose sharply as IMCIVREE sales expanded; 81% of FY 2023 product revenue came from the United States. A single U.S. customer accounted for approximately 77% of total revenue, and 67% of year-end accounts receivable was due from that customer.
- R&D spending increased with higher activity in the DAYBREAK, EMANATE and hypothalamic-obesity trials, additional staffing, RM-718 preclinical work and $5.7 million of acquired Xinvento in-process R&D expensed in 2023.
- SG&A rose with hiring and international commercial build-out. Cash flow from operations improved, but the company remained substantially loss-making.
- In January 2024, after year-end, Rhythm licensed worldwide rights to LB54640 from LG Chem. The disclosed terms include $40 million cash and $20 million in shares at closing, another $40 million cash payment 18 months later, up to $205 million in milestone payments, and potential royalties.
- The RIFA provides financing in exchange for tiered royalties on revenue, with a stated total repayment cap of 185%–250% of funded amounts and potential minimum-payment obligations. It may reduce cash available for operations.
Outlook, risks and contingencies
- Management expected to submit a U.S. application in the first half of 2024 to expand IMCIVREE use to children aged 2 to under 6; an EU application had been submitted. The Phase 3 hypothalamic-obesity trial was expected to report top-line results in the first half of 2025, and DAYBREAK Stage 2 data in the second half of 2024. These are forward-looking expectations, not reported outcomes.
- Key risks include reliance on one approved product, ongoing losses and possible need for further financing; uncertain clinical and regulatory outcomes; small and imprecisely estimated patient populations; reimbursement and market-access constraints; and dependence on third-party manufacturers, trial operators and suppliers.
- Setmelanotide’s reported adverse effects include skin hyperpigmentation, injection-site reactions, nausea and vomiting; the filing also discusses potential cardiovascular, sexual-function and other safety risks for MC4R agonists.
- Rhythm disputes its termination of the RareStone China license for cause; RareStone contests the termination. The company reported no material legal proceedings, but the disagreement may affect development or commercialization plans in the covered markets.
- Management and the auditor identified a material weakness in IT general controls over user access and program change management in a key financial reporting system. Management concluded internal control over financial reporting and disclosure controls were ineffective at December 31, 2023. The weakness did not result in a reported material misstatement; remediation was underway. The auditor issued an adverse opinion on internal control but an unqualified opinion on the financial statements.
- Other financial exposures include uninsured cash deposits above federal insurance limits, revenue concentration, and the RIFA’s royalty, minimum-payment and change-of-control provisions.
Important facts for investors to verify
- Subsequent quarterly filings: IMCIVREE sales trends, customer concentration, reimbursement access and whether the Medicaid documentation issue affecting some patients in Q4 2023 persisted.
- Cash burn and runway against the company’s second-half-2025 estimate, including the cash impact of the LB54640 license payments and RIFA obligations.
- Clinical-trial enrollment, safety and final results for hypothalamic obesity, EMANATE and DAYBREAK, and regulatory decisions on the pediatric label expansion.
- Progress in remediating the IT-control material weakness and any further auditor or management findings.
- Status and potential financial or operational consequences of the RareStone dispute, and whether financing or dilution becomes necessary.